stockportfolio.pro
Illumina, Inc. (ILMN)
Healthcare · Diagnostics & Research · NasdaqGS
Illumina, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2017 | 2018 | 2019 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.40B | $2.75B | $3.33B | $3.54B | $3.24B | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B |
| Gross profit | $1.67B | $1.83B | $2.30B | $2.47B | $2.20B | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B |
| Net income | $463.00M | $726.00M | $826.00M | $1.00B | $656.00M | $762.00M | $-4.40B | $-1.16B | $-1.22B | $850.00M |
| Net margin | 19.3% | 26.4% | 24.8% | 28.3% | 20.3% | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
Source: Illumina, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Illumina, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ILMN in your portfolio →
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Illumina, Inc. — frequently asked questions
What is Illumina, Inc.'s revenue?
Illumina, Inc. (ILMN) reported revenue of $4.34B for fiscal year 2025, down 0.7% from the prior year, according to its SEC filings.
Is Illumina, Inc. profitable?
Yes. ILMN earned net income of $850.00M in fiscal 2025, a net margin of 19.6%.
What is ILMN's P/E ratio?
Illumina, Inc. trades at a price-to-earnings ratio of about 29.6 based on the latest data in our nightly-refreshed cache.
How fast is Illumina, Inc. growing?
ILMN's revenue grew at roughly 6.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Illumina, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.